Loading organizations...
§ Private Profile · Lausanne, Switzerland
Swiss molecular cancer diagnostics company developing personalized diagnostic tests for oncology and early colon cancer screening.
Founded in 2005 by Jacques Essinger and CEO Stavros Therianos, Diagnoplex is a molecular cancer diagnostics company based in Switzerland that develops personalized diagnostic tests for early cancer screening. The organization primarily focuses on oncology solutions, specifically advancing clinical trials and commercialization strategies for its proprietary colon cancer screening product, which is known as Colox. To support its ongoing product development and strategic market expansion efforts across the broader healthcare sector, the enterprise successfully secured an impressive 8,300,000 dollars in Series A venture capital financing. This critical funding round was driven by notable strategic investors operating within the global pharmaceutical space, specifically including major industry leaders like Novartis and Debiopharm Group. Furthermore, Debiopharm Group has recently renewed its financial commitments to further back the clinical progression of the company's personalized medicine approaches and innovative molecular diagnostic testing platforms.
Diagnoplex has raised $20.8M across 4 funding rounds.
Diagnoplex has raised $20.8M in total across 4 funding rounds.
Diagnoplex has raised $20.8M in total across 4 funding rounds.
Diagnoplex's investors include Debiopharm Diagnostics, Initiative Capital Romandie, NeoMed Management, Novartis Venture Fund, Omega Funds, Debiopharm, Novartis.
Diagnoplex has raised $20.8M across 4 funding rounds. Most recently, it raised $1.4M Other Equity in June 2013.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 7, 2013 | $1.4M Venture Round | Debiopharm Diagnostics | Initiative Capital Romandie, Neomed Management | Announced |
| Jun 1, 2013 | $1M Series U | — | Novartis Venture Fund, Omega Funds | Announced |
| Jan 18, 2011 | $10.4M Series A Plus | Debiopharm | Initiative Capital Romandie, Neomed Management, Novartis | Announced |
| Dec 1, 2008 | $8M Series A | — | Novartis Venture Fund, Omega Funds | Announced |
# Diagnoplex: High-Level Overview
Diagnoplex is a Swiss diagnostic technology company developing non-invasive blood biomarker tests for early cancer detection, with an initial focus on colorectal cancer screening.[1][3] The company builds molecular assays using single-channel quantitative multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) technology to identify cancer biomarkers in blood samples.[1] Diagnoplex addresses a critical healthcare gap: while survival rates for colorectal cancer improve dramatically—up to 90%—when detected early, current screening methods suffer from low compliance due to their invasive nature.[6] The company serves healthcare systems and diagnostic laboratories seeking to improve cancer detection rates through accessible, patient-friendly screening solutions.
Diagnoplex has demonstrated meaningful traction in the European market, securing multiple financing rounds and establishing strategic partnerships. The company closed a CHF 10 million funding round and has partnered with Unilabs, a leading European diagnostic provider, to scale its molecular assay capabilities across the continent.[1][5] This combination of proprietary technology, clinical validation, and distribution partnerships positions Diagnoplex as a growing player in the precision diagnostics space.
# Core Differentiators
# Role in the Broader Tech Landscape
Diagnoplex operates within the broader shift toward liquid biopsy and non-invasive diagnostics, a trend driven by advances in molecular biology and growing demand for patient-centric healthcare solutions. The timing is particularly favorable: healthcare systems across Europe face pressure to improve cancer screening rates while managing costs, and patients increasingly prefer non-invasive alternatives. Diagnoplex's focus on colorectal cancer—one of the most prevalent cancers globally—addresses a market with substantial unmet need and regulatory tailwinds supporting innovation in screening technologies.
# Quick Take & Future Outlook
Diagnoplex is well-positioned to capture market share in European cancer screening as healthcare providers seek to modernize their diagnostic capabilities. The company's success will likely depend on clinical validation through prospective studies, regulatory approvals across key European markets, and the ability to scale manufacturing and distribution through partnerships like Unilabs. As precision diagnostics become increasingly central to preventive healthcare, Diagnoplex's non-invasive biomarker platform could evolve beyond colorectal cancer into broader oncology screening applications, potentially expanding its addressable market significantly.